CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification

Two studies presented at CROI 2018 support the idea that ART reaches everywhere in the body that it needs to, and that residual ongoing HIV replication comes from HIV infected cells that were archived before ART was started.

By Simon Collins for HIV i-Base

HIV Research Highlights From First Day of CROI 2018

A Facebook Live interview with NIAID Division of AIDS director Carl Dieffenbach, Ph.D., about some of the key research findings presented during the first full day of sessions at CROI 2018.


Once-Daily Tenofovir Alafenamide Appears Sufficient When Dosed With Rifampicin

A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.

By Polly Clayden for HIV i-Base

High Uptake and Use of Vaginal Ring for HIV Prevention Observed in Open-Label Study

Nearly 90 percent of participants in an open-label study of a vaginal ring infused with a drug to prevent HIV are using the monthly ring at least some of the time, according to data presented at CROI 2018.

By National Institute of Allergy and Infectious Diseases

CROI 2018 Preview: Using Our Tools for Better HIV Prevention and Treatment

It's strange to think about the Conference on Retroviruses and Opportunistic Infections (CROI) being the hottest ticket in town. But for the research community, CROI is in fact one of the more significant annual conferences on the latest HIV research...

By Kenyon Farrow

Substantial Statin Treatment Gap Exists for People Living With HIV

A 12-year analysis of the large NA-ACCORD cohort showed that more than half of those who could use a statin to treat their cardiovascular diseasehad not received a prescription for it.

By Project Inform

The Best HIV Cure Will Be Built With Us, Not Just for Us

"Without early and consistent partnership with the community in our efforts to incrementally develop a cure for HIV we may never achieve what people with HIV most hope a cure will offer them."

By Project Inform

Ibalizumab Is Effective at Reducing HIV Viral Load in People With Few Treatment Options

A study showed that a new monoclonal antibody drug called ibalizumab reduced viral loads in individuals with multi-drug resistant HIV. Adding the drug to a failing regimen may help treatment-experienced people who have few options to control their vi...

By Project Inform

Increased Risk of IRIS With Integrase Inhibitors Reported in Two Studies

Two cohort studies showed a higher risk of IRIS with integrase inhibitor-based ART than with other regimens.

By Polly Clayden for HIV i-Base

PREP in Pregnancy Does Not Increase Poor Birth Outcomes

No increase in poor birth outcomes with PrEP used throughout pregnancy in the Partners Demonstration project.

By Polly Clayden for HIV i-Base